Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.
May 13, 2013
Merrimack Reports First Quarter 2013 Financial Results
Jun 4, 2013 at 9:30 AM ET
Merrimack Pharmaceuticals To Present at Jefferies 2013 Global Healthcare Conference